

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/34245 A2

- (51) International Patent Classification⁷: **A61K 31/00**
- (21) International Application Number: **PCT/US01/27779**
- (22) International Filing Date: 23 October 2001 (23.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/242,899 24 October 2000 (24.10.2000) US
60/283,120 11 April 2001 (11.04.2001) US
60/314,218 22 August 2001 (22.08.2001) US
- (71) Applicants (*for all designated States except US*): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). **PHARMACIA AB** [SE/SE]; Lindhagensgatan 133, S-0112 87 Stockholm (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **GILLBERG, Per-Goran** [SE/SE]; Tallbacksvagen 44A, S-756 45 Uppsala (SE). **SUNDQUIST, Staffan** [SE/SE]; Sturgatan 25, S-561 45 Huskvarna (SE). **CAMMARATA, Sue, K.** [US/US]; 10147 Point O' Woods Drive, Portage, MI 49002 (US).
- (74) Agent: **STEIN, Bruce**; Global Intellectual Property, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF TOLTERODINE TO TREAT ASTHMA

(57) Abstract: The present invention is a method of treating a mammal selected from the group consisting of humans and horses who has asthma, COPD or allergic rhinitis and is need of such treatment by inhaling an anti-asthma, anti-COPD anti-allergic rhinitis effective amount, respectively, of a compound selected from the group consisting of tolterodine hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate and pharmaceutically acceptable salts thereof.

WO 02/34245 A2

USE OF TOLTERODINE TO TREAT ASTHMACROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Nos. 60/242,899 filed October 24, 2000, 60/283,120 filed April 11, 2001, 60/314,218 filed August 22, 2001, under 35 USC 119(e)(i). The entire disclosure of which is herein incorporated by reference.

BACKGROUND OF THE INVENTION1. Field of the Invention

The present invention is a new use for tolterodine and a few other similar compounds to treat asthma, a group of breathing disorders termed Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis.

2. Description of the Related Art

US Patent 5,382,600 discloses 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol also known as N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine with the generic name of tolterodine as being useful to treat urinary incontinence. *Drug Metabolism and Disposition*, 26(4), 289-293 (1998) discloses that tolterodine is a muscarinic receptor antagonist.

US Patent 5,559,269 and *Drug Metabolism and Disposition*, 26(4), 289-293 (1998) disclose hydroxytolterodine. US Patent 5559,269 discloses this compound as useful to treat urinary incontinence. *Pharmacol. Toxicol.*, 81, 169-172 (1997) discloses that hydroxytolterodine has antimuscarinic activity.

US Patent 6,124,354 discloses 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate, see Example 99, and its use in treating urinary incontinence and irritable bowel syndrome. *Can. J. Chem.*, 40, 1909-1916 (1962) refers to this compound as a potential antidote for treatment of anticholinesterase poisoning. *J. Am. Chem. Soc.*, 69, 2902-2906 (1947) while not mentioning the diisopropylamino compound but a diethylamino analog, discusses that the diethylamino compound has antispasmodic action against acetylcholine.

It is known that antimuscarinic compounds are used in the treatment of asthma and COPD.

The antimuscarinic compound ipratropium has been approved for use in treating allergic rhinitis.

SUMMARY OF INVENTION

Disclosed is a method of treating a mammal selected from the group consisting of humans and horses that have asthma and are in need of such treatment by inhaling an anti-asthma effective amount of a compound selected from the group consisting of
5 tolterodine, hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate or a pharmaceutically acceptable salt thereof.

Also disclosed is a method of treating a mammal selected from the group consisting of humans and horses that have COPD and are in need of such treatment by inhaling an anti-COPD effective amount of a compound selected from the group
10 consisting of tolterodine, hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate or a pharmaceutically acceptable salts thereof.

Further disclosed is a method of treating a mammal selected from the group consisting of humans and horses that has allergic rhinitis and is in need of such treatment by inhaling an anti-allergic rhinitis effective amount of a compound selected
15 from the group consisting of tolterodine, hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate or a pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

US Patent 5,382,600 discloses tolterodine (Example 22) and that it is useful to
20 treat urinary incontinence. Tolterodine is presently being sold in a number of different countries for that purpose. When tolterodine is used to treat urinary incontinence it is administered orally. It is preferred that tolterodine be prepared by the process of International Publication WO98/29402.

Hydroxytolterodine and 2-(diisopropylamino)ethyl-1-
25 phenylcyclopentanecarboxylate are also known compounds. For convenience, these three compounds collectively will be referred to as ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS. It is preferred that the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENT be tolterodine.

The present invention is the use of the ANTI-ASTHMA/ANTI-COPD/ANTI-
30 ALLERGIC RHINITIS AGENTS to treat asthma, COPD and allergic rhinitis.

The method of the present invention is used to treat mammals including humans and horses. It is preferred that the mammal be a human.

The compounds of the present invention are administered by inhalation. The inhalation can be by either an aerosol or a powder.

An anti-asthma, anti-COPD and anti-allergic rhinitis effective amount of ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS is from about 0.05 mg to about 12 mg. It is preferred that the anti-asthma, anti-COPD and anti-allergic rhinitis effective amount is from about 0.1 to about 6 mg; it is more preferred that the anti-asthma, anti-COPD and anti-allergic rhinitis effective amount is from about 0.2 to about 5 mg.

The ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS can be administered from one thru four times daily. It is preferable to administer the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS two or three times daily, more preferable twice daily.

The minimum amount of an aerosol delivery is about 0.2 ml and the maximum aerosol delivery is about 5 ml. The concentration of the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS is not critical so long as the total amount of spray delivered is within the about 0.2 to about 5 ml amount and it delivers an anti-asthma, anti-COPD and anti-allergic rhinitis effective amount. It is well known to those skilled in the art that if the concentration is higher, one gives a smaller dose to deliver the same "effective amount". The non-active ingredient or carrier can be (sterile) water with the pH adjusted to where the active anti-asthma pharmaceutical agent is very soluble. It is preferred that the pH be at or near 7. Alternatively and preferably, the non-active carrier agent should be physiological saline with the pH adjusted appropriately. Aerosols for inhalation of various pharmaceutical agents are well known to those skilled in the art including many aerosols for treating asthma, COPD and allergic rhinitis. There is nothing special in the present invention regarding the aerosol.

Alternatively the dosage form for inhalation can be a powder. Powders for inhalation of various pharmaceutical agents are well known to those skilled in the art including many powders for treating asthma, COPD and allergic rhinitis. There is nothing special in the present invention regarding the powder. When the dosage form is a powder, the active pharmaceutical agent can be administered in pure form or diluted with an inert carrier. When an inert carrier is used, the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENT pharmaceutical agent

is compounded such that the total amount of powder delivered delivers an "effective amount" of the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENT. The actual concentration of the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENT is not critical. If the concentration is lower, then more powder must be delivered; if the concentration is higher, less total material must be delivered to provide an effective amount of one of the ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS.

Various devices are on the market for administering powders for inhalation for asthma, COPD and allergic rhinitis and these devices are suitable for administering the compounds of the present invention.

Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The pharmaceutically acceptable salts are preferred over the corresponding free amines since they produce compounds that are more water soluble and more crystalline. The preferred pharmaceutically acceptable salts include salts of the following acids hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, citric, methanesulfonic $\text{CH}_3-(\text{CH}_2)_{n_1}-\text{COOH}$ where n_1 is 0 thru 4, $\text{HOOC}-(\text{CH}_2)_{n_1}-\text{COOH}$ where n is as defined above, $\text{HOOC}-\text{CH}=\text{CH}-\text{COOH}$, $\phi-\text{COOH}$. For other acceptable salts, see *Int. J. Pharm.*, 33, 201-217 (1986).


DEFINITIONS

All temperatures are in degrees Celsius.

COPD refers to Chronic Obstructive Pulmonary Disease.


Allergic rhinitis refers to acute rhinitis or nasal rhinitis.

Tolterodine refers to 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol also known as N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, a compound of the formula:




(R)-stereoisomer

Hydroxytolterodine refers to 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, a compound of the formula:



(R)-stereoisomer

2-[Bis(1-methylethyl)amino]ethyl-1-phenylcyclopentanecarboxylate also known as 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate, a compound of the formula:



5

ANTI-ASTHMA/ANTI-COPD/ANTI-ALLERGIC RHINITIS AGENTS refers to tolterodine, hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate.

Physiological saline refers to a 0.9% aqueous sodium chloride solution.

10

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

When solvent pairs are used, the ratios of solvents used are volume/volume

15 (v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).

FEV₁ refers to Force Expiratory Volume in one second.

FEV₁/FVC refers to the ratio of the Force Expiratory Volume/Force Vital

20 Capacity.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever.

Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

EXAMPLE 1

A 65 year old female with a history of chronic COPD with FEV₁ of 1.5 liters is treated with tolterodine aerosol 1 mg every 12 hr continuously for dyspnea. After two weeks of therapy dyspnea tolerance is improved.

EXAMPLE 2

A 50 year old male with a history of chronic COPD with FEV₁/FVC of 60% liters is treated with hydroxyltolterodine aerosol 2 mg every 8 hr continuously for dyspnea. After a week of treatment the FEV₁/FVC ratio improves to about 65%.

EXAMPLE 3

A 25 year old female with a history of asthma with a morning peak flow of less than 2 l/sec is treated with 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate powder 0.1 mg every 8 hr continuously. Treatment improves the peak flow to 4-5 l/sec.

EXAMPLE 4

A 35 year old male with a history of severe asthma with a morning peak flow of 5 l/sec is treated with tolterodine powder 6 mg once a day continuously. After a week of treatment the peak flow improves to 9 l/sec.

EXAMPLE 5

A 45 year old female with a history of severe asthma with a morning peak flow of less than 3 l/sec is treated with tolterodine aerosol 2 mg three times daily continuously. After a week of treatment the peak flow improves to 6 l/sec.

CLAIMS

1. A method of treating a mammal selected from the group consisting of humans and horses that have asthma and are in need of such treatment by inhaling an anti-asthma effective amount of a compound selected from the group consisting of tolterodine,
5 hydroxytolterodine and 2-(diisopropylamino)ethyl-1- phenylcyclopentanecarboxylate or a pharmaceutically acceptable salt thereof.
2. A method of treatment according to claim 1 where the mammal is a human.
- 10 3. A method of treatment according to claim 1 where the inhalation is with an aerosol.
4. A method of treatment according to claim 1 where the inhalation is with a powder.
- 15 5. A method of treatment according to claim 1 where the anti-asthma effective amount is from about 0.05 mg to about 12 mg.
6. A method of treatment according to claim 5 where the anti-asthma effective amount is from about 0.1 to about 6 mg.
- 20 7. A method of treatment according to claim 6 where the anti-asthma effective amount is from about 0.2 to about 5 mg.
8. A method of treatment according to claim 1 where the compound is tolterodine.
- 25 9. A method of treating a mammal selected from the group consisting of humans and horses that have COPD and are in need of such treatment by inhaling an anti-COPD effective amount of a compound selected from the group consisting of tolterodine, hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate
30 or a pharmaceutically acceptable salt thereof.
10. A method of treatment according to claim 9 where the mammal is a human.

11. A method of treatment according to claim 8 where the inhalation is with an aerosol.
12. A method of treatment according to claim 11 where the inhalation is with a powder.
13. A method of treatment according to claim 9 where the anti-asthma effective amount is from about 0.05 mg to about 12 mg.
14. A method of treatment according to claim 13 where the anti-asthma effective amount is from about 0.1 to about 6 mg.
15. A method of treatment according to claim 14 where the anti-asthma effective amount is from about 0.2 to about 5 mg.
16. A method of treatment according to claim 9 where the compound is tolterodine.
17. A method of treating a mammal selected from the group consisting of humans and horses that have allergic rhinitis and are in need of such treatment by inhaling an anti-allergic rhinitis effective amount of a compound selected from the group consisting of tolterodine, hydroxytolterodine and 2-(diisopropylamino)ethyl-1-phenylcyclopentanecarboxylate or a pharmaceutically acceptable salt thereof.
18. A method of treatment according to claim 17 where the mammal is a human.
19. A method of treatment according to claim 17 where the inhalation is with an aerosol.
20. A method of treatment according to claim 1 where the inhalation is with a powder.
21. A method of treatment according to claim 1 where the anti-allergic rhinitis effective amount is from about 0.05 mg to about 12 mg.

22. A method of treatment according to claim 21 where the anti-allergic rhinitis effective amount is from about 0.1 to about 6 mg.

5 23. A method of treatment according to claim 6 where the anti-allergic rhinitis effective amount is from about 0.2 to about 5 mg.

24. A method of treatment according to claim 17 where the compound is tolterodine.

10

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.